This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to TNF. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of TNF. TNF-FuP provided a weak stimulus for lymphocyte proliferation, but it had no effect on LAK cells. However, it supported activation of Mfs and, to a minor extent, of CTLs. This immunocytokine was designed for treating CD30-positive lymphoma.